NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free GPCR Stock Alerts $38.94 -0.04 (-0.10%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$37.85▼$39.4650-Day Range$33.90▼$45.8052-Week Range$21.79▼$75.02Volume972,500 shsAverage Volume572,990 shsMarket Capitalization$1.81 billionP/E RatioN/ADividend YieldN/APrice Target$85.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Structure Therapeutics alerts: Email Address Structure Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside120.1% Upside$85.71 Price TargetShort InterestBearish9.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.98) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 starsMedical Sector679th out of 916 stocksPharmaceutical Preparations Industry303rd out of 416 stocks 3.5 Analyst's Opinion Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.92% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Structure Therapeutics has recently increased by 9.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GPCR. Previous Next 2.5 News and Social Media Coverage News SentimentStructure Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Structure Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for GPCR on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Structure Therapeutics are expected to grow in the coming year, from ($0.98) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -46.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -46.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 3.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Structure Therapeutics Stock (NASDAQ:GPCR)Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.Read More GPCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GPCR Stock News HeadlinesApril 24, 2024 | investorplace.com3 Speculative Weight Loss Drug Stocks to Bet On for Big GainsApril 20, 2024 | americanbankingnews.comCantor Fitzgerald Reiterates Overweight Rating for Structure Therapeutics (NASDAQ:GPCR)April 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 18, 2024 | msn.comBig pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.April 18, 2024 | theglobeandmail.comAnalysts Expect This 'Strong Buy' Weight-Loss Stock to DoubleApril 16, 2024 | finance.yahoo.comStructure Therapeutics Inc. (GPCR)April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Structure Therapeutics on Upcoming GSBR-1290 Phase 2a Data OptimismApril 10, 2024 | markets.businessinsider.comBuy Rating for Structure Therapeutics on Strong Obesity Drug Prospects and Strategic PartnershipsApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 9, 2024 | msn.comCantor starts Structure at overweight, sees positive data for GLP-1 drugMarch 30, 2024 | investorplace.com7 Small-Cap Stocks that Wall Street Loves for Good ReasonMarch 20, 2024 | finance.yahoo.comGPCR Dec 2024 50.000 callMarch 17, 2024 | finance.yahoo.comGPCR Sep 2024 30.000 putMarch 16, 2024 | finance.yahoo.comGPCR May 2024 30.000 putMarch 16, 2024 | finance.yahoo.comGPCR Apr 2024 30.000 putMarch 15, 2024 | msn.comGPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023March 13, 2024 | bizjournals.comFormer CFO sues Peninsula drug company, alleges domestic violence incident led to her firingMarch 10, 2024 | finance.yahoo.comWe Think Structure Therapeutics (NASDAQ:GPCR) Can Afford To Drive Business GrowthMarch 9, 2024 | finance.yahoo.comGPCR Mar 2024 40.000 putMarch 8, 2024 | globenewswire.comStructure Therapeutics to Present at Leerink Partners Global Biopharma ConferenceMarch 8, 2024 | globenewswire.comStructure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent HighlightsMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Structure Therapeutics Amidst Competitive Landscape and Promising Drug ProspectsFebruary 23, 2024 | benzinga.comStructure Therapeutics Stock (NASDAQ:GPCR), Short Interest ReportFebruary 23, 2024 | benzinga.comStructure Therapeutics Stock (NASDAQ:GPCR) Dividends: History, Yield and DatesFebruary 20, 2024 | ca.finance.yahoo.comGPCR Mar 2024 60.000 callFebruary 18, 2024 | seekingalpha.comBaron Opportunity Fund Q4 2023 Shareholder LetterFebruary 1, 2024 | msn.comResearchers develop method to map interactions of specific RNA regions in live cellsSee More Headlines Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today4/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GPCR CUSIPN/A CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees93Year FoundedN/APrice Target and Rating Average Stock Price Target$85.71 High Stock Price Target$97.00 Low Stock Price Target$65.00 Potential Upside/Downside+120.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.69% Return on Assets-30.50% Debt Debt-to-Equity RatioN/A Current Ratio19.14 Quick Ratio19.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.77 per share Price / Book3.99Miscellaneous Outstanding Shares46,600,000Free FloatN/AMarket Cap$1.81 billion OptionableOptionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Raymond C. Stevens Ph.D. (Age 60)CEO & Director Comp: $747.33kDr. Yingli Ma Ph.D. (Age 50)Chief Technology Officer Comp: $497.58kDr. Mark A. Bach M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $628.37kMr. Jun S. Yoon (Age 46)Co- Founder, CFO & Secretary Dr. Xichen Lin Ph.D. (Age 50)Chief Scientific Officer Mr. Tony PengSenior Vice President of LegalMr. Bob GatmaitanSenior Vice President of PeopleDr. Hui Lei Ph.D.Senior Vice President of ChemistryDr. Fang Zhang Ph.D.Executive VP & Head of BiologyMs. Lani IbarraSenior Vice President of Clinical Development OperationsMore ExecutivesKey CompetitorsAmneal PharmaceuticalsNASDAQ:AMRXSupernus PharmaceuticalsNASDAQ:SUPNAvadel PharmaceuticalsNASDAQ:AVDLHarmony BiosciencesNASDAQ:HRMYCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 7,300 shares on 4/25/2024Ownership: 0.000%Allspring Global Investments Holdings LLCSold 816 shares on 4/18/2024Ownership: 0.101%TrueMark Investments LLCBought 3,562 shares on 4/15/2024Ownership: 0.064%Wellington Management Group LLPBought 3,504,747 shares on 3/5/2024Ownership: 9.426%Goldman Sachs Group Inc.Bought 356,302 shares on 3/1/2024Ownership: 0.922%View All Institutional Transactions GPCR Stock Analysis - Frequently Asked Questions Should I buy or sell Structure Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GPCR shares. View GPCR analyst ratings or view top-rated stocks. What is Structure Therapeutics' stock price target for 2024? 6 equities research analysts have issued 1-year price objectives for Structure Therapeutics' stock. Their GPCR share price targets range from $65.00 to $97.00. On average, they anticipate the company's share price to reach $85.71 in the next twelve months. This suggests a possible upside of 120.1% from the stock's current price. View analysts price targets for GPCR or view top-rated stocks among Wall Street analysts. How have GPCR shares performed in 2024? Structure Therapeutics' stock was trading at $40.76 on January 1st, 2024. Since then, GPCR shares have decreased by 4.5% and is now trading at $38.94. View the best growth stocks for 2024 here. Are investors shorting Structure Therapeutics? Structure Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 4,110,000 shares, an increase of 9.9% from the March 31st total of 3,740,000 shares. Based on an average daily volume of 553,100 shares, the short-interest ratio is presently 7.4 days. Approximately 9.9% of the company's shares are sold short. View Structure Therapeutics' Short Interest. When is Structure Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GPCR earnings forecast. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. (NASDAQ:GPCR) released its quarterly earnings results on Friday, March, 8th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. What ETFs hold Structure Therapeutics' stock? ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), Alger Mid Cap 40 ETF (FRTY), Tema Cardiovascular and Metabolics ETF (HRTS), American Century Focused Dynamic Growth ETF (FDG). When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Structure Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%), TrueMark Investments LLC (0.06%) and Simplex Trading LLC (0.00%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GPCR) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryHas Jeff Bezos Found the Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
